180 Wealth Advisors LLC Buys 12,300 Shares of GRAIL, Inc. $GRAL

180 Wealth Advisors LLC lifted its position in GRAIL, Inc. (NASDAQ:GRAL) by 10.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 127,347 shares of the company’s stock after purchasing an additional 12,300 shares during the period. GRAIL accounts for about 0.7% of 180 Wealth Advisors LLC’s investment portfolio, making the stock its 26th biggest position. 180 Wealth Advisors LLC’s holdings in GRAIL were worth $6,581,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Royal Bank of Canada increased its holdings in GRAIL by 17.7% during the 1st quarter. Royal Bank of Canada now owns 88,082 shares of the company’s stock worth $2,250,000 after purchasing an additional 13,264 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of GRAIL by 28.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock worth $76,000 after buying an additional 623 shares during the period. NewEdge Advisors LLC lifted its holdings in shares of GRAIL by 390.3% in the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock worth $45,000 after buying an additional 1,401 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of GRAIL by 37.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 92,465 shares of the company’s stock worth $2,362,000 after buying an additional 25,177 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of GRAIL by 115.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 79,544 shares of the company’s stock worth $4,090,000 after buying an additional 42,675 shares in the last quarter.

Insider Activity at GRAIL

In other news, insider Andrew John Partridge sold 1,491 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $61.08, for a total transaction of $91,070.28. Following the completion of the sale, the insider owned 163,738 shares in the company, valued at approximately $10,001,117.04. This represents a 0.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.83% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on GRAL. Piper Sandler lifted their price objective on GRAIL from $54.00 to $56.00 and gave the company a “neutral” rating in a report on Wednesday, May 6th. Mizuho assumed coverage on shares of GRAIL in a report on Friday, April 10th. They set a “neutral” rating and a $58.00 target price on the stock. Wall Street Zen raised shares of GRAIL from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Guggenheim reduced their price target on shares of GRAIL from $130.00 to $75.00 and set a “buy” rating for the company in a report on Monday, March 30th. Finally, The Goldman Sachs Group assumed coverage on shares of GRAIL in a research report on Friday, June 5th. They issued a “neutral” rating and a $60.00 price target for the company. Four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $67.00.

GRAIL Price Performance

Shares of GRAL stock traded down $3.79 during mid-day trading on Friday, hitting $72.00. 509,860 shares of the stock traded hands, compared to its average volume of 564,771. GRAIL, Inc. has a 52-week low of $29.95 and a 52-week high of $118.84. The stock has a market cap of $3.09 billion, a P/E ratio of -6.94 and a beta of 3.22. The stock’s fifty day moving average is $64.29 and its two-hundred day moving average is $70.02.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($2.29) EPS for the quarter, topping the consensus estimate of ($2.76) by $0.47. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. The firm had revenue of $40.78 million during the quarter, compared to analyst estimates of $39.16 million. As a group, equities analysts forecast that GRAIL, Inc. will post -10.91 EPS for the current fiscal year.

GRAIL News Summary

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: No clearly positive company-specific catalysts were reported in the latest batch of articles.
• Neutral Sentiment: Several law firms, including Rosen, Berger Montague, Schall, Faruqi & Faruqi, Levi & Korsinsky, and others, are reminding investors about the ongoing class action and the August 4, 2026 lead plaintiff deadline, keeping the legal issue in focus. Article Title
• Neutral Sentiment: Robbins LLP and other firms are urging stockholders who bought shares during the alleged class period to contact them for information about joining the lawsuit, suggesting the case is still actively being marketed to affected investors. Article Title
• Negative Sentiment: The core negative takeaway is that the lawsuit centers on the February 20, 2026 trial update, which reportedly erased more than $2.2 billion in market value and is now being framed as securities fraud, a headline that can weigh on investor sentiment. Article Title

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.